Growth hormone
Somapacitan
An albumin-binding GH derivative with a pediatric noninferiority trial and product-specific indications that now extend beyond GH deficiency.
Randomized pediatric GH-deficiency comparison; indication-specific evidence
Also known as: Sogroya · Somapacitan-beco
Practical use
Clinical context and evidence interpretation
- Identify the diagnosis
- Keep GH deficiency, small-for-gestational-age short stature, Noonan syndrome and idiopathic short stature distinct when reading a result.
- Track growth consistently
- For a clinical discussion, use dated height measurements and the team’s growth chart instead of a single snapshot.
- Discuss burden honestly
- Ask about convenience, response and side effects as separate dimensions; fewer administrations alone does not answer all three.
Overview
Somapacitan binds reversibly to albumin to prolong GH activity. Current US Sogroya labeling includes adult GH deficiency and, from age 2.5, GH-deficient growth failure, specified short stature after birth small for gestational age, Noonan syndrome and idiopathic short stature. The REAL4 trial below specifically studied GH deficiency.
Risks and limitations
Warnings include glucose intolerance, intracranial hypertension, fluid retention and changes in adrenal or thyroid status. Active malignancy and specified critical illnesses are contraindications. Persistent headache with visual changes, or a child’s new limp or hip/knee pain, needs prompt clinical assessment.
How to read this
A wider label does not make one trial answer every indication. Preserve the diagnosis beside any growth figure and do not rank long-acting products by comparing numbers from unrelated trials.
Research explained
REAL4: growth compared with daily GH
Who was studied
200 treatment-naive children with GH deficiency randomized 2:1 to somapacitan or daily somatropin; open-label multinational trial, primary assessment at 52 weeks.
- Somapacitan: height velocity
- 11.2 cm/year
- Daily GH: height velocity
- 11.7 cm/year
What was found
Mean height velocity was 11.2 versus 11.7 cm/year. Somapacitan met the prespecified noninferiority criterion. Injection-site reactions were reported in 5.3% versus 5.9%. Treatment burden improved more with somapacitan, while disease-burden improvements were similar.
What it cannot establish
Noninferiority allows a predefined margin; it does not mean numerical equality or superior growth. One-year growth does not establish final adult height. An open-label treatment-burden report can be influenced by awareness of the regimen.
Read the original studyConvenience and efficacy are separate outcomes
REAL4 provides evidence for comparable growth within its margin and lower reported treatment burden. A more convenient delivery pattern should not be described as inherently stronger or safer.
Supporting sourceAn IGF-1 value has a timing context
Long-acting GH creates an IGF-1 profile across the treatment interval. Product identity and the timing recorded by the clinical team matter when comparing laboratory results.
Supporting sourceClaims versus findings
Not established
All growth indications have exactly the REAL4 response.
REAL4 enrolled children with GH deficiency. Other labeled diagnoses have their own clinical evidence and expected response.
Check the evidenceCommon questions
Can 11.2 cm/year be compared directly with a different product’s separate trial?
That is an indirect comparison. Baseline age, diagnosis, severity and design can differ; a head-to-head study would answer the comparison more directly.
SourceSources
REAL4: growth compared with daily GH
US prescribing information; checked October 1, 2026
Sources checked 2026-10-01.
General education; not a personal treatment plan.